Silvio E. Inzucchi MDProfessor of Medicine (Endocrinology); Clinical Director, Section of Endocrinology; Director, Yale Diabetes Center; Director, Endocrinology and Metabolism Fellowship, Yale School of Medicine, New Haven, Connecticut
Dr. Silvio Inzucchi is professor of medicine at the Yale University School of Medicine in New Haven, Connecticut, where he serves as the clinical chief of the Section of Endocrinology, program director of the Endocrinology and Metabolism Fellowship, and the medical director of the Yale Diabetes Center.
Dr. Inzucchi received his medical degree from Harvard Medical School, in Boston, Massachusetts. He completed his residency in internal medicine and his post-doctoral fellowship in endocrinology and metabolism at Yale–New Haven Hospital.
Dr. Inzucchi has been an invited lecturer, both nationally and internationally, on many topics, most pertaining to clinical diabetes management. He has authored or coauthored more than 500manuscripts, chapters, and abstracts, some published in the foremost medical journals, including The New England Journal of Medicine and JAMA. He has served on editorial boards for numerous scientific journals, including Diabetes Care and the Journal of Clinical Endocrinology & Metabolism.
Dr. Inzucchi has a large academic clinical practice involving a wide spectrum of patients with endocrine diseases, with a focus on diabetes and pituitary/adrenal diseases. His current research interests include anti-hyperglycemic therapy in both the inpatient and outpatient settings and the link among type 2 diabetes, insulin resistance, and cardiovascular complications.
Professor of Medicine, Yale University School of Medicine; Clinical Chief, Section of Endocrinology; Program Director, Endocrinology and Metabolism Fellowship; Director, Yale Diabetes Center, New Haven, Connecticut.
MD: Harvard Medical School
Fellowship (endocrinology and metabolism): Yale–New Haven Hospital, New Haven, Connecticut
Clinical Interests: Anti-hyperglycemic therapy; the link among type 2 diabetes, insulin resistance, and cardiovascular complications
The following are Dr. Silvio Inzucchi's disclosures:
Advisor: Merck, vTv Therapeutics, Abbott/Alere, Zafgen
Clinical Trial Steering/Executive/Publications Committee Member and related consulting activities: AstraZeneca, Boehringer Ingelheim, Sanofi/Lexicon, Novo Nordisk
Recent Contributions to PracticeUpdate:
- Patient With CV Co-morbidities and Adverse Events to Metformin and Glyburide: Next Steps?
- Practical Considerations and Utility of SGLT2 Inhibitors in Improving CV Outcomes
- An Overview of Cardiovascular Outcome Trials (CVOTs) in Type 2 Diabetes
- Semaglutide vs Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise
- ADA 2018: Clinically Relevant Data on Pioglitazone and CV Risk Reduction
- Risk of Amputations Associated With SGLT2 Inhibitors Compared With DPP-4 Inhibitors
- Modifying Diabetes Drug Therapy in the Presence of Renal Disease
- ADA 2018: Critical Changes in the New ADA Guidelines for Type 2 Diabetes
- ADA Scientific Sessions 2018: Recommendations From Dr. Silvio Inzucchi
- Metabolic Syndrome Is Associated With Lower Neurocognitive Function in Middle-Aged Hispanics/Latinos